EP1858527A1 - Formes de dosage oral de derives de gemcitabine - Google Patents

Formes de dosage oral de derives de gemcitabine

Info

Publication number
EP1858527A1
EP1858527A1 EP06716760A EP06716760A EP1858527A1 EP 1858527 A1 EP1858527 A1 EP 1858527A1 EP 06716760 A EP06716760 A EP 06716760A EP 06716760 A EP06716760 A EP 06716760A EP 1858527 A1 EP1858527 A1 EP 1858527A1
Authority
EP
European Patent Office
Prior art keywords
gemcitabine
dosage form
oral dosage
pharmaceutical acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06716760A
Other languages
German (de)
English (en)
Other versions
EP1858527A4 (fr
Inventor
Ole Henrik Eriksen
Marit Liland Sandvold
Finn Myhren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clavis Pharma ASA
Original Assignee
Clavis Pharma ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clavis Pharma ASA filed Critical Clavis Pharma ASA
Publication of EP1858527A1 publication Critical patent/EP1858527A1/fr
Publication of EP1858527A4 publication Critical patent/EP1858527A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2',2'-difluorodeoxycytidine (Gemcitabine).
  • the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in treatment of cancer.
  • Gemcitabine has the formula:
  • R 1 , R 2 and R 3 are independently selected from hydrogen and C 18 - and C 2 o- saturated and monounsaturated acyl groups, with the proviso that R 1 , R 2 and R 3 cannot all be hydrogen.
  • gemcitabine is a well known cytostatic compound, marketed under the trade name Gemzar by Eli Lilly & Co.
  • Gemzar is administered intravenously (i.v.).
  • the reason for choosing a parenteral administration route is due to the toxicity of gemcitabine.
  • gemcitabine Like a lot of drugs, it obviously would have been desirable to be able to administer gemcitabine orally.
  • oral administration usually is much more pleasant than intravenous administration.
  • R 1 , R 2 and R 3 are independently selected from hydrogen and C 18 - and C 2 o- saturated and monounsaturated acyl groups, with the proviso that R 1 , R 2 and R 3 cannot all be hydrogen or a pharmaceutical acceptable salt thereof, for preparing an oral dosage form ameliorating compliance in treatment of cancer, is provided.
  • Gemcitabine has three derivatisable functions, namely the 5'- and 3'-hydroxyl groups and the N 4 -amino group. Each group can selectively be transformed into an ester or amide derivative, but di-adducts (di-esters or ester-amides) and tri-adducts may be formed as well. In the case of the di- and tri-adducts the acyl substituent groups need not necessarily be the same.
  • the mono-acyl derivatives of this invention i.e. with two of R 1 , R 2 and R 3 being hydrogen, are preferred. It is especially preferred that the monosubstitution with the acyl group should be in the 3'-0 and 5'-O positions of the sugar moiety, with 5'-0 substitution being most preferred.
  • the double bond of the mono-unsaturated acyl groups may be in either the cis or the trans configuration, although the therapeutic effect may differ depending on which configuration is used.
  • the position of the double bond in the monounsaturated acyl groups also seem to affect the activity.
  • esters or amides having their unsaturation in the ⁇ -9 position.
  • the position ⁇ of the double bond of a monounsaturated fatty acid is counted from the terminal methyl group, so that, for example, eicosenoic acid (C 2 o: 1 ⁇ -9) has 20 carbon atoms in the chain and a single double bond is formed between carbon 9 and 10 counting from the methyl end of the chain.
  • Esters, ester-amides and amides of gemcitabine derived from stearic acid (C 18 :0) and eicosanoic acid (C 2O ⁇ O) are advantageously used in some cases.
  • elaidic acid (5')-gemcitabine ester for preparing an oral dosage form ameliorating compliance in treatment of cancer.
  • the present invention relates to an oral dosage form useful for ameliorating compliance in treatment of cancer, comprising a gemcitabine derivative of formula (I) or a pharmaceutical acceptable salt thereof.
  • the present invention also provides a method for ameliorating compliance in treatment of cancer, in a subject in need of such treatment, which comprises orally administering to such subject a therapeutically effective amount of a gemcitabine derivative of formula (T) as defined in claim 1 or a pharmaceutical acceptable salt thereof.
  • terapéuticaally effective amount refers to from about 0,1 mg to 20 grams per day of a gemcitabine derivative of formula (I) or a pharmaceutical acceptable salt thereof, more preferred from about 100 mg to 2 grams per day of a gemcitabine derivative of formula (I) or a pharmaceutical acceptable salt thereof, in a formulation containing 0,001 - 100% of the said derivative or salt thereof formulated in capsule, tablet, mixture, colloidal suspension or others for oral administration.
  • a gemcitabine derivative of formula (I) or a pharmaceutical acceptable salt thereof in a formulation containing 0,001 - 100% of the said derivative or salt thereof formulated in capsule, tablet, mixture, colloidal suspension or others for oral administration.
  • Fig. 1 shows antitumour activity of elaidic acid (5')-gemcitabine ester and gemcitabine in colon cancer xenograft Co5776.
  • Fig. 2 shows antitumour activity of elaidic acid (5')-gemcitabine ester and gemcitabine after intraperitoneal administration to mice with human colon cancer xenograft Co6044.
  • Fig. 3 shows oral effect of elaidic acid (5')-gemcitabine ester in Co6044 xenograft.
  • Fig. 4 shows mean body weight of treated animals.
  • the maximum tolerated dose for gemcitabine is approximately 120 mg/kg per injection compared to 40 mg/kg per injection for elaidic acid (5')-gemcitabine ester. This is shown below by the experiments presented in table 1 and table 2 using different mice strains and also different human colon xenografts.
  • BWC body weight change
  • T/C volume of treated tumour versus volume of control tumour
  • Ncr nu/nu female mice, 8 per group, were inserted with the human colon cancer xenograft Co6044 and treated IP every third day for five times with elaidic acid (5')- gemcitabine ester (40mg/kg) or gemcitabine (120 mg/kg) . Treatment started when the tumours reached a mean volume of 100 mm 3 . Excellent antitumor effect was obtained for elaidic acid (5')-gemcitabine ester and gemcitabine.
  • Antitumour activity after oral administration of elaidic acid (5')-gemcitabine ester and gemcitabine was tested for the first time in NCR:nu/nu mice. The lowest starting dose was selected based on IP data. A dose of gemcitabine that is well tolerated and active when administered intraperitoneally (120 mg/kg per injection) was highly toxic and it was impossible to evaluate antitumour activity as gemcitabine was toxic at all tested doses. On the contrary and to our great surprise, a dose of elaidic acid (5')-gemcitabine ester (40 mg/kg) that was shown to be highly active after intraperitoneal administration was also highly active and tolerable when given orally. These results are shown in Table 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des formes de dosage oral de certains dérivés d'acides gras saturés et mono-insaturés à chaîne longue de 2',2'-difluorodéoxycytidine (Gemcitabine). L'invention concerne, en particulier, l'utilisation de dérivés de gemcitabine ou d'un sel pharmaceutiquement acceptable de ceux-ci pour préparer une forme de dosage oral permettant d'améliorer l'adhésion au traitement d'un cancer.
EP06716760A 2005-03-18 2006-03-07 Formes de dosage oral de derives de gemcitabine Withdrawn EP1858527A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20051467A NO322682B1 (no) 2005-03-18 2005-03-18 Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
PCT/NO2006/000085 WO2006098628A1 (fr) 2005-03-18 2006-03-07 Formes de dosage oral de derives de gemcitabine

Publications (2)

Publication Number Publication Date
EP1858527A1 true EP1858527A1 (fr) 2007-11-28
EP1858527A4 EP1858527A4 (fr) 2010-10-27

Family

ID=35267108

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06716760A Withdrawn EP1858527A4 (fr) 2005-03-18 2006-03-07 Formes de dosage oral de derives de gemcitabine

Country Status (13)

Country Link
US (1) US20080280851A1 (fr)
EP (1) EP1858527A4 (fr)
JP (1) JP2008533135A (fr)
KR (1) KR20070120539A (fr)
AU (1) AU2006223757A1 (fr)
CA (1) CA2600399A1 (fr)
IL (1) IL185866A0 (fr)
NO (1) NO322682B1 (fr)
NZ (1) NZ561377A (fr)
RU (1) RU2007138582A (fr)
UA (1) UA90893C2 (fr)
WO (1) WO2006098628A1 (fr)
ZA (1) ZA200707979B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
WO2010039039A1 (fr) * 2008-10-03 2010-04-08 Clavis Pharma Asa Formulations orales de dérivés de gemcitabine
CN101525361B (zh) * 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2729180B1 (fr) 2011-07-08 2019-01-23 The University of North Carolina At Chapel Hill Nanoparticules de métal-bisphosphonate pour thérapie anticancéreuse et imagerie, ainsi que pour traiter des troubles des os
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
KR20150082606A (ko) 2012-11-13 2015-07-15 보옌 테라퓨틱스, 인크. 겜시타빈 전구약물 및 그의 용도
EP3065713B1 (fr) 2013-11-06 2024-03-06 The University of Chicago Vecteurs nanométriques pour l'administration ou la co-administration d'agents chimiothérapeutiques, d'acides nucléiques et de photosensibilisateurs
US10463684B2 (en) 2014-01-29 2019-11-05 Board Of Regents, The Uneversety Of Texas System Nucleobase analogue derivatives and their applications
EP3439666A4 (fr) 2016-05-20 2019-12-11 The University of Chicago Nanoparticules pour chimiothérapie, thérapie ciblée, thérapie photodynamique, immunothérapie et n'importe quelle combinaison de ces dernières
CN107184592A (zh) * 2017-05-17 2017-09-22 广东艾时代生物科技有限责任公司 吉西他滨在制备治疗类风湿性关节炎药物中的应用
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
EP3746134A1 (fr) 2018-02-02 2020-12-09 Maverix Oncology, Inc. Conjugués de médicaments à petites molécules de monophosphate de gemcitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327358C (fr) * 1987-11-17 1994-03-01 Morio Fujiu Derives fluorocytidine
JP4352115B2 (ja) * 1997-01-24 2009-10-28 クラヴィス・ファルマ・アーエスアー ゲムシタビン誘導体
AU2003291726A1 (en) * 2002-11-04 2004-06-07 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, BERGMAN, A. M. ET AL: "Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Gemcitabine in Leukemia and Solid Tumor Cell Lines and in Human Xenografts" XP002601241 retrieved from STN Database accession no. 2004:913123 & BERGMAN, A. M. ET AL: "Antiproliferative Activity and Mechanism of Action of Fatty Acid Derivatives of Gemcitabine in Leukemia and Solid Tumor Cell Lines and in Human Xenografts" 2004, NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS , 23(8 & 9), 1329-1333 CODEN: NNNAFY; ISSN: 1525-7770 *
IMMORDINO M L ET AL: "Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs" JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.JCONREL.2004.09.001, vol. 100, no. 3, 10 December 2004 (2004-12-10), pages 331-346, XP004656456 ISSN: 0168-3659 *
See also references of WO2006098628A1 *

Also Published As

Publication number Publication date
NZ561377A (en) 2009-10-30
AU2006223757A1 (en) 2006-09-21
US20080280851A1 (en) 2008-11-13
ZA200707979B (en) 2008-11-26
NO322682B1 (no) 2006-11-27
RU2007138582A (ru) 2009-04-27
EP1858527A4 (fr) 2010-10-27
CA2600399A1 (fr) 2006-09-21
NO20051467D0 (no) 2005-03-18
WO2006098628A1 (fr) 2006-09-21
KR20070120539A (ko) 2007-12-24
JP2008533135A (ja) 2008-08-21
UA90893C2 (ru) 2010-06-10
IL185866A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
WO2006098628A1 (fr) Formes de dosage oral de derives de gemcitabine
US20070225248A1 (en) Oral dosage forms of gemcitabine derivatives
AU2022204373B2 (en) Cytarabine conjugates for cancer therapy
WO2002043765A3 (fr) Formulations pharmaceutiques contenant du paclitaxel, ses derives et ses sels pharmaceutiquement acceptables
JP6002835B2 (ja) 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
JPH10505578A (ja) 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
ES2414617T3 (es) Ácidos grasos de cadena de longitud media, sales y triglicéridos en combinación con gemcitabina para el tratamiento del cáncer pancreático
KR100812693B1 (ko) 항종양 효과 증강제 및 항종양제
KR100853955B1 (ko) 아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물
JP2020176071A (ja) 血液がんの新規治療法及び新規治療剤
US20210315898A1 (en) Combination therapy for treating cancer
KR100861668B1 (ko) 치환된 아크릴로일 디스타마이신 유도체, 탁산 및/또는 항대사물질을 포함하는, 항종양 배합 치료제
JPH07277964A (ja) 抗腫瘍剤
US20210338704A1 (en) Cytarabine conjugates for cancer therapy
TWI827864B (zh) 血液癌之新穎治療法及新穎治療劑
WO2022014025A1 (fr) Nouvelle méthode thérapeutique et nouvel agent thérapeutique pour le cancer hématologique
WO2021172490A1 (fr) Médicament combiné, et médicament prévenant ou inhibant l'apparition de résistance à un antimétabolite de pyrimidine
EP2331091A1 (fr) Combinaison pharmaceutique de 1-(2-tétrahydrofuryle)-5-fluorouracile et d'ester phénéthylique d'acide caféique, destinée au traitement buccal de tumeurs
Spreafico et al. Factors modifying the activity and toxicity of anticancer agents
WO2024030998A2 (fr) Méthodes de traitement du cancer avec un inhibiteur de topoisomérase i à action prolongée
Tagliabue et al. Antitumor activity of 1, 4-bis (2'-chloroethyl)-l, 4-diazabicyclo-[2.2. 1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX
EP1200099A1 (fr) Composition a synergie comportant des derives daunorubicines et des composes antimetabolites
JPH0558892A (ja) 発癌防止剤
JPH0316921B2 (fr)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ERIKSEN, OLE, HENRIK

Inventor name: MYHREN, FINN

Inventor name: SANDVOLD, MARIT, LILAND

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110429